大农化

Munich-based cultivated meat startup MyriaMeat has established a pluripotent stem cell (iPSC) line from roe deer and successfully produced functional roe deer muscle cells using its patented differentiation protocol, the company announced this week.

Novvia Group has obtained APC Packaging, a supplier of luxury beauty packaging solutions, including plastic and glass containers, closures, and packaging components. The financial terms of the acquisition have not been disclosed. 

Two Swedish companies, biotech firm Curve (formerly Re:meat AB) and software company Digital Tvilling AB, have announced a partnership to develop an integrated biomanufacturing platform that uses AI and digital twin technology to reduce the cost of precision fermentation over time.

Protein Industries Canada (PIC) has committed $4.9 million to a $15.1 million project with NS/TX Industries, New Protein International (NPI), and Infusd Nutrition to automate and expand NS/TX’s whole-cut alternative protein manufacturing platform.

Los Angeles-based coffee chain The Coffee Bean & Tea Leaf will remove its upcharge for plant-based milk alternatives starting June 3, following a campaign by animal rights organization PETA that included outreach from more than 20,000 supporters and a direct meeting with the company.

Karlijn Sibbel, Chief Innovation Officer at seaweed and plant-based packaging company Notpla, will join eXXpedition’s South Pacific research voyage this June, bringing the perspective of the alternative materials sector to a scientific mission tracing plastic pollution through ocean and land ecosystems.

Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets and based on stabilized helical peptides or Helicons™, has filed for an initial public offering (IPO), joining a growing parade of companies seeking to raise capital by tapping into the improving market for first time biotech stocks.

The positive opinion covers the use of Wegovy pill to reduce excess body weight and maintain long-term weight reduction in adults with obesity, or overweight with at least one weight-related comorbidity. According to Novo Nordisk, the opinion also includes data from the SELECT cardiovascular outcomes trial, showing that semaglutide reduces the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.

Some types of cancer have a relentless appetite for the metabolite cholesterol, using as much as they can access to accelerate their growth beyond the capabilities of normal cells. Research by scientists at Sanford Burnham Prebys Medical Discovery Institute and collaborators at the University of Illinois Chicago have now unveiled a potential method for turning the table on these tumors by subverting their cholesterol cravings.